Today, SAFC announced the launch of the CHOZN® Platform System to accelerate recombinant protein drug development. The new platform allows faster and simpler selection of high producing clones for use in recombinant protein drugs, as well as facilitating a more efficient scale-up process. The full press release is available below.
St. Louis, Mo. – April 11, 2012 – Sigma-Aldrich Corporation (NASDAQ: SIAL) today announced that its custom manufacturing and services business unit, SAFC® (www.safcglobal.com), is launching the CHOZN® Platform system, a CHO (Chinese Hamster Ovary) cell expression system that allows for faster, simpler selection and scale-up of high-producing clones for the production of recombinant protein drugs. The new platform consists of the cGMP-produced and tested CHOZN® ZFN Modified GS-/- CHO cell line, an optimized set of cGMP-produced, chemically defined media and specially designed feeds to maximize production of r-proteins. The CHOZN® Platform system has been designed and tested to perform from initial cell line engineering process and stable cell line selection, through large-scale growth and production, providing an off-the-shelf production solution for biopharmaceutical developers who do not currently have a cell line platform. Used for the production of biopharmaceuticals, the CHOZN® GS-/- cell line is the first commercially available glutamine synthetase (GS) knockout CHO line proven to shorten bioproduction times in early development, enabling customers to enhance their speed to market and decrease costs. For more information about the CHOZN Platform, visit www.safcglobal.com/choznplatform.
Along with the cells, media and feed, SAFC provides extensive user protocols covering transfection through scale-up to small scale bioreactors, as well as comprehensive cell line safety testing and development history.
“The CHOZN Platform system provides a solid foundation for SAFC’s continued cell and media development program,” says Bruce Lehr, SAFC Director of Cell Sciences and Development. “It has been proven to show a reduction in product development timelines, enabling customers to get their molecules into the clinic faster. Furthermore, it sets the stage for future cell line enhancements to affect characteristics like protein quality, molecule safety and efficacy, as well as improvements to upstream or downstream biopharmaceutical process development.”
The CHOZN Platform follows the 2011 release of the CHOZN GS-/- and CHOZN DHFR-/- CHO lines.
For more information on SAFC’s CHOZN Cell Lines, visit: www.safcglobal.com/chozn
For more information on SAFC’s CompoZr ZFN offer, visit: www.safcglobal.com/zfnkits
For more information on SAFC’s Cell Design Studio (CDS) offer, visit: www.safcglobal.com/cces